Why the study?
Current guidelines recommend vitamin K antagonists as the preferred treatment for left atrial appendage thrombus, despite emerging evidence that direct oral anticoagulants may be safer and preferred.
Does DOAC treatment reduce the incidence and improve the resolution of left atrial appendage thrombus compared to VKA in patients with nonvalvular atrial fibrillation?
Does DOAC treatment reduce the incidence and improve the resolution of left atrial appendage thrombus compared to VKA in patients with nonvalvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
DOACs are superior to VKAs in reducing the incidence and promoting the resolution of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
Background: Left atrial appendage thrombus (LAAT) is the main cause of cardioembolism in patients with nonvalvular atrial fibrillation (AF). Emerging evidence indicates that direct oral anticoagulants (DOACs) may be a preferred, safer choice for patients with LAAT. However, current guidelines indicate vitamin K antagonist (VKA) as the preferred treatment for LAAT. We conducted a meta-analysis to compare the efficacy of VKA and DOAC for the treatment of LAAT. Methods: The search was conducted in the PubMed, Embase, Google Scholar, and Cochrane Library databases from inception to July 2022, with the language restricted to English. A first analysis was conducted to evaluate the risk of LAAT under VKA or DOAC treatment. A second analysis was conducted to compare the resolution of LAAT under VKA and DOAC treatment. Results: In 13 studies comparing LAAT incidence rates under VKA and DOAC treatment, significant superiority of DOAC was detected (pooled RR = 0.65, 95% CI = 0.47–0.90, p = 0.009) with moderate heterogeneity being identified in the pooled studies. In 13 studies comparing LAAT resolution under VKA and DOAC use, treatment with DOAC exhibited a significantly increased probability of LAAT resolution compared with VKA (pooled odds ratio = 1.52, 95% CI = 1.02–2.26, p = 0.040). Conclusions: This meta-analysis suggests a superiority of DOAC over VKA with respect to LAAT incidence in people with AF and the likelihood of LAAT resolution. Due to their established safety profile, DOAC is a preferable choice for anticoagulation, although further randomized controlled studies are warranted to provide further evidence of their suitability as a new recommended treatment.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: